Our study demonstrated that providing clinicians, both cardiologists and PCPs, with a simple blood test to provide a 4-year risk stratification score increased use of evidence-based pharmacologic treatments in patients with T2DM, namely SGLT2 inhibitors and GLP1 receptor antagonists. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.